Capital Analysts LLC’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.05M | Sell |
48,615
-1,671
| -3% | -$134K | 0.08% | 205 |
|
|
2025
Q4 | $4.79M | Buy |
50,286
+1,589
| +3% | +$156K | 0.13% | 132 |
|
|
2025
Q3 | $4.75M | Sell |
48,697
-1,364
| -3% | -$141K | 0.14% | 131 |
|
|
2025
Q2 | $5.38M | Buy |
50,061
+602
| +1% | +$60.9K | 0.18% | 105 |
|
|
2025
Q1 | $4.99M | Buy |
49,459
+822
| +2% | +$82.8K | 0.19% | 102 |
|
|
2024
Q4 | $4.34M | Buy |
48,637
+728
| +2% | +$64.1K | 0.17% | 106 |
|
|
2024
Q3 | $4.01M | Buy |
47,909
+3,697
| +8% | +$291K | 0.16% | 114 |
|
|
2024
Q2 | $3.4M | Buy |
44,212
+2,027
| +5% | +$148K | 0.15% | 117 |
|
|
2024
Q1 | $2.89M | Buy |
42,185
+974
| +2% | +$62.6K | 0.13% | 132 |
|
|
2023
Q4 | $2.38M | Buy |
41,211
+868
| +2% | +$46.3K | 0.12% | 146 |
|
|
2023
Q3 | $2.13M | Buy |
40,343
+302
| +0.8% | +$15.8K | 0.12% | 144 |
|
|
2023
Q2 | $2.17M | Sell |
40,041
-626
| -2% | -$32.7K | 0.12% | 147 |
|
|
2023
Q1 | $2.04M | Sell |
40,667
-12,954
| -24% | -$611K | 0.12% | 155 |
|
|
2022
Q4 | $2.48M | Sell |
53,621
-1,809
| -3% | -$78.3K | 0.15% | 134 |
|
|
2022
Q3 | $2.15M | Sell |
55,430
-296
| -0.5% | -$11.9K | 0.15% | 135 |
|
|
2022
Q2 | $2.08M | Sell |
55,726
-350
| -0.6% | -$14.2K | 0.14% | 141 |
|
|
2022
Q1 | $2.48M | Buy |
56,076
+1,694
| +3% | +$73.4K | 0.16% | 127 |
|
|
2021
Q4 | $2.31M | Buy |
54,382
+1,135
| +2% | +$47.7K | 0.14% | 143 |
|
|
2021
Q3 | $2.31M | Buy |
53,247
+2,097
| +4% | +$92.8K | 0.15% | 135 |
|
|
2021
Q2 | $2.19M | Buy |
51,150
+11,872
| +30% | +$499K | 0.15% | 138 |
|
|
2021
Q1 | $1.52M | Buy |
39,278
+4,761
| +14% | +$180K | 0.1% | 167 |
|
|
2020
Q4 | $1.24M | Buy |
34,517
+3,979
| +13% | +$143K | 0.11% | 156 |
|
|
2020
Q3 | $1.17M | Buy |
30,538
+2,403
| +9% | +$92.6K | 0.11% | 149 |
|
|
2020
Q2 | $988K | Buy |
28,135
+37
| +0.1% | +$1.33K | 0.1% | 154 |
|
|
2020
Q1 | $917K | Sell |
28,098
-559
| -2% | -$21.8K | 0.11% | 147 |
|
|
2019
Q4 | $1.3M | Buy |
28,657
+1,391
| +5% | +$58.2K | 0.13% | 153 |
|
|
2019
Q3 | $1.11M | Buy |
27,266
+147
| +0.5% | +$6.23K | 0.12% | 159 |
|
|
2019
Q2 | $1.17M | Sell |
27,119
-1,605
| -6% | -$61.7K | 0.13% | 147 |
|
|
2019
Q1 | $1.1M | Sell |
28,724
-8,932
| -24% | -$341K | 0.13% | 142 |
|
|
2018
Q4 | $1.33M | Sell |
37,656
-3,992
| -10% | -$145K | 0.17% | 100 |
|
|
2018
Q3 | $1.6M | Buy |
41,648
+691
| +2% | +$24.1K | 0.18% | 98 |
|
|
2018
Q2 | $1.34M | Sell |
40,957
-76
| -0.2% | -$2.29K | 0.16% | 102 |
|
|
2018
Q1 | $1.12M | Buy |
41,033
+2,322
| +6% | +$63.1K | 0.14% | 123 |
|
|
2017
Q4 | $960K | Buy |
+38,711
| New | +$1.07M | 0.12% | 142 |
|
Other funds holding BSX
VCM
VPM
Capital Analysts LLC's BSX Position: Q1 2026 in Review
Capital Analysts LLC reduced its Boston Scientific (BSX) stake by 3.3% in Q1 2026, selling an estimated $134K and leaving 48,615 shares worth $3.05M. The position accounts for 0.08% of the portfolio, ranked #205.
Capital Analysts LLC first reported a position in BSX in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.38M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Capital Analysts LLC held 48,615 shares of Boston Scientific worth $3.05M as of Q1 2026.
- Capital Analysts LLC sold 1,671 Boston Scientific shares in Q1 2026, an estimated $134K.
- Boston Scientific made up 0.08% of Capital Analysts LLC's portfolio in Q1 2026, its #205 holding.
- Capital Analysts LLC first reported a position in Boston Scientific in Q4 2017 and has held it in 34 quarters since.
- Capital Analysts LLC's Boston Scientific position peaked at $5.38M in Q2 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.